Advertisement

Techniques in Coloproctology

, Volume 23, Issue 1, pp 79–80 | Cite as

Pyoderma gangrenosum as first manifestation of Crohn’s disease

  • A. Rizzuto
  • G. Gallo
  • M. TrompettoEmail author
  • R. Sacco
The Last Image
  • 33 Downloads

Notes

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. This article does not contain any studies with animals performed by any of the authors.

Informed consent

Informed consent was obtained from the participant included in the study.

References

  1. 1.
    Halling ML, Kjeldsen J, Knudsen T, Nielsen J, Hansen LK (2017) Patients with inflammatory bowel disease have increased risk of autoimmune and inflammatory diseases. World J Gastroenterol 23:6137–6146CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Arguelles-Arias F, Castro-Laria L, Lobaton T et al (2013) Characteristics and treatment of pyoderma gangrenosum in inflammatory bowel disease. Dig Dis Sci 58:2949–2954CrossRefPubMedGoogle Scholar
  3. 3.
    Hagen JW, Swoger JM, Grandinetti LM (2015) Cutaneous manifesta tions of Crohn disease. Dermatol Clin 33:417–431CrossRefPubMedGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Department of Medical and Surgical SciencesUniversity of CatanzaroCatanzaroItaly
  2. 2.Department of Colorectal SurgeryS. Rita ClinicVercelliItaly

Personalised recommendations